Detalhe da pesquisa
1.
Soluble Guanylyl Cyclase Activator BI 685509 Reduces Portal Hypertension and Portosystemic Shunting in a Rat Thioacetamide-Induced Cirrhosis Model.
J Pharmacol Exp Ther
; 386(1): 70-79, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37230799
2.
The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease.
J Pharmacol Exp Ther
; 384(3): 382-392, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36507845
3.
Effect of Novel Biotherapeutic Elevating Angiopoietin 1 on Progression of Diabetic Nephropathy in Diabetic/Obese Mice.
J Pharmacol Exp Ther
; 382(3): 266-276, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35779860
4.
A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 Rat.
J Pharmacol Exp Ther
; 356(3): 712-9, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26729306
5.
G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a K(Ca)1.1 (BK(Ca))-dependent mechanism.
J Pharmacol Exp Ther
; 348(3): 421-31, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24399854
6.
Mitigation of off-target adrenergic binding and effects on cardiovascular function in the discovery of novel ribosomal S6 kinase 2 inhibitors.
J Pharmacol Exp Ther
; 340(3): 492-500, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22128344
7.
Strategic integration of in vivo cardiovascular models during lead optimization: predictive value of 4 models independent of species, route of administration, and influence of anesthesia.
J Cardiovasc Pharmacol
; 59(4): 369-76, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22179024
8.
Discovery of a Series of Pyrazinone RORγ Antagonists and Identification of the Clinical Candidate BI 730357.
ACS Med Chem Lett
; 12(1): 143-154, 2021 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33488976
9.
Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition.
J Pharmacol Exp Ther
; 329(3): 928-37, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19255283
10.
ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats.
J Cardiovasc Pharmacol
; 53(2): 173-8, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19188829
11.
Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure.
J Pharmacol Exp Ther
; 325(1): 331-40, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18171907
12.
Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
J Med Chem
; 50(22): 5439-48, 2007 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17918921
13.
Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice.
Nephron Physiol
; 106(4): p76-81, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17622742
14.
Predictive, non-GLP models of secondary pharmacodynamics: putting the best compounds forward.
Curr Opin Chem Biol
; 9(4): 392-9, 2005 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15950522
15.
Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
J Med Chem
; 49(22): 6439-42, 2006 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-17064063
16.
Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists.
J Med Chem
; 49(7): 2339-52, 2006 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-16570930
17.
Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety.
J Med Chem
; 49(22): 6569-84, 2006 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-17064075
18.
Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.
J Med Chem
; 49(21): 6416-20, 2006 Oct 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-17034148
19.
Cardiovascular disease in chronic kidney failure: the role of VDR activators.
Curr Opin Investig Drugs
; 7(3): 206-13, 2006 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-16555680
20.
12-lipoxygenase in opioid-induced delayed cardioprotection: gene array, mass spectrometric, and pharmacological analyses.
Circ Res
; 92(6): 676-82, 2003 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-12623876